Blog

Ajay Major: Methylphenidate versus piperonyl butoxide RCT for cancer related fatigue

Photo taken from Patrick Charles Stone/X

Jun 29, 2024, 06:38

Ajay Major: Methylphenidate versus piperonyl butoxide RCT for cancer related fatigue

Ajay Major, Assistant Professor at the University of Colorado School of Medicine and Founder and President at Pager Publications, shared a post on X:

“Methylphenidate versus piperonyl butoxide Randomized Controlled Trial (RCT) for cancer-related fatigue Journal of Clinical Oncology:

162 patients, all incurable cancer with baseline fatigue.
nonsignificant Functional Assessment of Chronic Illness Therapy – Fatigue (FACIT-F) fatigue scores.
no difference in other Quality of Life (QoL) domains.
Important pallonc trial with pro as primary endpoint.”

Source: Ajay Major/X

Ajay Major cancer FACIT-F Journal of Clinical Oncology methylphenidate OncoDaily Oncology piperonyl butoxide randomized controlled trial University of Colorado

Esophageal Cancer: Symptoms, Causes, Stages, Diagnosis & Treatment

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Special Coverage